PepTalk 2017
PepTalk 2017

Pipeline Four Header

Cambridge Healthtech Institute’s Third Annual
CHO Cell Lines
Enhancing Expression, Performance and Process
January 11-12, 2017 | Hilton San Diego Bayfront | San Diego, CA


CHO cells’ rapid rise in production prominence is due to their adaptability to various culture conditions, gene plasticity, and ability in proper folding, posttranslational modifications, and glycosylation of desired proteins. Thus, advances in CHO cell lines and culture continue to significantly improve biotherapeutic production. This achievement is due to progress in engineering stable and transient cell lines, enhancing cell culture conditions and performance, as well as optimizing process development. When all are accomplished, higher-production titers and better product quality result. The CHO Cell Lines conference gathers cell line engineers, cell culture specialists and bioprocess development managers to explore the latest data, tools and strategies for improving protein expression, production, and product quality.

Preliminary Agenda


ENGINEERING HIGH(ER) PRODUCERS

A Predictable, Plug-and-Play Cell Culture Platform Process

James Lambropoulos, Engineer III, Cell Culture Development, Biogen

In the Pursuit of High Producers: Use of the Sony SH800 Cell Sorter for the Selection of Cell Lines with Superior Productivity Characteristics

Nadia Amharref, Ph.D., Scientist, Cell Line Development, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH

Engineering Protein Production Hosts

Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark


IMPROVING PRODUCT QUALITY

Chromatin Function Modifying Elements in an Industrial Antibody Production Platform

Mark Ellis, Principal Scientist, Protein Expression and Purification, UCB Pharma

Cell Line Profiling to Improve Productivity and Product Quality

Sohye Kang, Ph.D., Senior Scientist, Amgen

Product Quality and Protein Expression in CHO Cells

Pauline Smidt, Process Design Scientist, Just Biotherapeutics


OPTIMIZING PRODUCTION AND PROCESS


FEATURED PRESENTATION: Genome-Scale Big Data and Modeling Approaches to Optimizing Protein Production in CHO Cells

Bernhard Palsson, Ph.D., Galletti Professor, Bioengineering; Professor, Pediatrics; Principal Investigator, Systems Biology Research Group, Bioengineering, University of California, San Diego


Upgrading CHO Clone Selection and Bioprocess Development by Metabolic Modeling Approaches

Oliver Popp, Ph.D., Senior Scientist, Pharma Research and Early Development, Cell Culture Research, Roche Innovation Center, Roche Diagnostics GmbH




For questions about the meeting, please contact:

Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5497
Email: mabrown@healthtech.com

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com